SOHM Inc (SHMN)

[PENNIEStoSTACKS]

Company Overview
SOHM, Inc. (SHMN) is a pharmaceutical manufacturer that produces and markets generic drugs for all
major treatment categories. In February, 2009, the Company obtained a direct manufacturing license
under Current Good Manufacturing Practice (CGMP) and initiated processes to be compliant with World
Health Organization (WHO) regulations to produce generic as well as OTC pharmaceuticals. This
authorization process provides the Company with manufacturing competencies for a wide variety of
products covering various therapeutic segments. SHMN has private label license agreements with two
companies to produce pharmaceuticals and OTC products.
The Company’s strategic manufacturing facility enables low production costs without compromising
quality. SHMN develops, manufactures and markets generic pharmaceuticals in various dosage forms,
including tablets and capsules, creams and topicals, ointments, liquids and injectables. At present, SHMN
has global licenses to manufacture more than 15 products and approximately 300 generic drugs and
product formulations for distribution.
SHMN markets and sells its generic drugs globally but focuses primarily on emerging markets in Africa,
Latin America, Southeast Asia and the European Union. The Company’s global headquarters is located in
North America and it has offices in China, India and the U.K.
Generic Drug Manufacturing Expertise
SHMN’s proprietary processes and formulation capability allow it to develop generic formulations of
brand name drugs that don’t infringe on valid patents relating to the brand-name product. Demand for
generic pharmaceuticals is increasing as a result of increasing awareness and acceptance of generics by
consumers, physicians and pharmacists globally. In addition, government agencies and private managed
care/ insurance programs encourage the substitution of generics for brand-name pharmaceuticals as a cost
savings measure. SHMN has developed ability to bridge the gap between demand and supply for generic
and OTC products cost effectively with consistent quality deliverables.
Infrastructure To Support Manufacturing and Export
By consolidating its pharmaceutical assets in India, the Company has a generic drug manufacturing hub
where it capitalizes on low prices, strong marketing and global recognition of Indi’s emerging role as a
leading drug manufacturing center. In October 2008, SHMN obtained pharmaceutical drug licenses that
enable it to sell in Africa, Latin America and Southeast Asia. In February 2009, SHMN obtained a direct
manufacturing license for generic pharmaceuticals. This license completes the needed infrastructure
development for its India manufacturing hub.